Philip Stroisch

Philip Stroisch is an experienced professional currently serving as the Head of Investor Relations and Communications at CureVac since 2020, where responsibilities include leading the investor relations and corporate communications team to enhance the equity story and ensure cohesive messaging. Stroisch has held various leadership positions at CureVac, including Chief of Staff, where collaboration with the CEO and leadership team focused on mRNA-based medicines, and Program Head of Strategic Restructuring and Transformation, overseeing significant workforce restructuring to prioritize research and innovation. Prior to CureVac, Stroisch was an Entrepreneur in Residence at Kytos Therapeutics and held roles in corporate development and strategy at InGeneron, in addition to internships at various organizations including Uber and Robert Bosch Venture Capital. Stroisch's educational background includes a Master of Science from the Technical University of Munich and fellowships at institutions such as the University of California, Berkeley and ETH Zürich.